Influenza vaccines licensed in the United States in healthy children: a systematic review and network meta-analysis (Protocol)

Table 1 Evidence profile

Quality assessment							Number of patients		Effect		Quality	Importance
Number of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	LAIV	IIV	RR (95% CI)	Absolute
Laboratory confirmed influenza (follow-up; assessed with: PCR or viral culture)
	Randomized trials										⊕ ⊕ ⊕ ⊕ HIGH	CRITICAL
Influenza like illness (follow-up; assessed with)
	Randomized trials										⊕ ⊕ ⊕ ⊕ HIGH	IMPORTANT
Hospitalization (follow-up; assessed with)
	Randomized trials										⊕ ⊕ ⊕ ⊕ HIGH	CRITICAL
Medically attended respiratory illness (follow-up; assessed with)
	Randomized trials										⊕ ⊕ ⊕ ⊕ HIGH	CRITICAL
Fever due to vaccination (follow-up mean, assessed with)
	Randomized trials										⊕ ⊕ ⊕ ⊕ HIGH	IMPORTANT
Guillain-Barre syndrome (follow-up mean, assessed with)
	Observational study										⊕ ⊕ ΟΟ LOW	IMPORTANT
Anaphylaxis (follow-up mean, assessed with)
	Observational study										⊕ ⊕ ΟΟ LOW	CRITICAL

Question: Should LAIV versus IIV be used for influenza?
Settings: healthy children.
CI, confidence interval; IIV, inactivated influenza vaccines; LAIV, live-attenuated influenza vaccines; RR; relative risk.

ISSN: 2046-4053